Source:http://linkedlifedata.com/resource/pubmed/id/19967557
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-9-16
|
| pubmed:abstractText |
Several gene expression profiles have been reported to predict breast cancer response to neoadjuvant chemotherapy. These studies often consider breast cancer as a homogeneous entity, although higher rates of pathologic complete response (pCR) are known to occur within the basal-like subclass. We postulated that profiles with higher predictive accuracy could be derived from a subset analysis of basal-like tumors in isolation. Using a previously described "intrinsic" signature to differentiate breast tumor subclasses, we identified 50 basal-like tumors from two independent clinical trials associated with gene expression profile data. 24 tumor data sets were derived from a 119-patient neoadjuvant trial at our institution and an additional 26 tumor data sets were identified from a published data set (Hess et al. J Clin Oncol 24:4236-4244, 2006). The combined 50 basal-like tumors were partitioned to form a 37 sample training set with 13 sequestered for validation. Clinical surveillance occurred for a mean of 26 months. We identified a 23-gene profile which predicted pCR in basal-like breast cancers with 92% predictive accuracy in the sequestered validation data set. Furthermore, distinct cluster of patients with high rates of cancer recurrence was observed based on cluster analysis with the 23-gene signature. Disease-free survival analysis of these three clusters revealed significantly reduced survival in the patients of this high recurrence cluster. We identified a 23-gene signature which predicts response of basal-like breast cancer to neoadjuvant chemotherapy as well as disease-free survival. This signature is independent of tissue collection method and chemotherapeutic regimen.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1573-7217
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
123
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
691-9
|
| pubmed:meshHeading |
pubmed-meshheading:19967557-Adult,
pubmed-meshheading:19967557-Aged,
pubmed-meshheading:19967557-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19967557-Breast Neoplasms,
pubmed-meshheading:19967557-Chemotherapy, Adjuvant,
pubmed-meshheading:19967557-Clinical Trials as Topic,
pubmed-meshheading:19967557-Cluster Analysis,
pubmed-meshheading:19967557-Disease-Free Survival,
pubmed-meshheading:19967557-Female,
pubmed-meshheading:19967557-Gene Expression Profiling,
pubmed-meshheading:19967557-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19967557-Genetic Testing,
pubmed-meshheading:19967557-Humans,
pubmed-meshheading:19967557-Kaplan-Meier Estimate,
pubmed-meshheading:19967557-Middle Aged,
pubmed-meshheading:19967557-Neoadjuvant Therapy,
pubmed-meshheading:19967557-Neoplasms, Basal Cell,
pubmed-meshheading:19967557-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:19967557-Predictive Value of Tests,
pubmed-meshheading:19967557-Reproducibility of Results,
pubmed-meshheading:19967557-Time Factors,
pubmed-meshheading:19967557-Treatment Outcome
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.
|
| pubmed:affiliation |
Department of Surgery, Washington University School of Medicine St. Louis, 660 South Euclid Avenue, Campus Box 8109, St. Louis, MO 63110, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|